Navin Fluorine International Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Mixed quarter with a sharp demand surprise: Specialty chemicals posted its highest-ever quarterly sales (up 31% YoY), but a plant breakdown cost nearly four weeks of production and demand volatility kept the outlook fluid.
• The high-margin restart is a material tailwind: A large, high-margin molecule from Surat that had dropped to near-zero demand is now restarting two quarters ahead of schedule, promising a margin lift from Q3 onward.
• CDMO is building a non-fluorination bridge: The new Fermion supply agreement, while not take-or-pay, validates the division's ability to supply molecules outside its core fluorination chemistry and opens a new growth vector.
• Honeywell volumes remain a moving target: Management declined to quantify the contract's supply progress or margin structure, and acknowledged that volume forecasts are revised monthly, making the recovery path hard to model.
• What to watch next quarter: Whether the Surat high-margin molecule actually ramps to full capacity, the pace of Honeywell volume catch-up, and the naming of a new CDMO CEO.

Specialty Chemicals: The Surprise Restart

• Record sales, volume-led: The segment delivered its highest-ever quarterly revenue of INR230 crores, a 31% YoY jump, driven entirely by new product introductions and volume rather than pricing. The order flow continues to strengthen long-term visibility.
• The Surat molecule gap: One large, high-margin molecule supplied from Surat saw demand drop almost to zero in the first half of calendar year 2023, creating a visible hole in standalone numbers and dragging on overall margins.
• Restart pulled forward: Supply has now restarted and a forecast has been received for H2 CY23. The plant is expected to run to full capacity from Q3 onward, a recovery management had not expected until the end of Q4 CY23.
• Margin mix mechanics: New molecules carry higher margins than the legacy portfolio, so directionally margins will keep expanding. The Surat molecule's restart will positively impact both specialty and overall business margins.
• Conscious pharma exit: Management is deliberately reducing the pharma portion of the specialty business, calling it not long-term sustainable or profitable, and exiting low-margin products.

Welling: "We were actually not expecting this uptick to happen so quickly. We were actually expecting it to start from only end of Q4 calendar year '23, but we have actually received that almost two quarters ahead."

Honeywell Contract: Volume Volatility and Capacity Expansion

• Q1 miss, catch-up promised: Volume missed in Q1 due to a planned HFO plant shutdown in April and an unplanned downstream equipment failure in June that cost nearly four weeks of production. Management expects to make up the shortfall in Q2 and Q3.
• Forecast, not a commitment: Management clarified there is no fixed volume negotiated, only a rolling six-month forecast from Honeywell that changes constantly. In June, strong end-product sell-through led to an upward revision.
• Debottlenecking in advanced talks: Discussions to add 25% capacity are in advanced stages, with closure expected within calendar year 2023. Capex would be completed by end of calendar year 2024, making the additional capacity available from the beginning of calendar year 2026.
• Contract expansion under negotiation: Management is negotiating to add the debottlenecked volume to the initial \$410 million contract. Post-debottlenecking, the company will also evaluate adding another line for the same product.
• Opacity on progress: Management declined to disclose what percentage of the \$410 million contract has been supplied so far, or the margin structure, citing confidentiality.

CDMO: Fermion Win and Leadership Transition

• Strong quarter, shifting mix: CDMO revenue grew 33% YoY to INR93 crores. The sales mix is shifting: last year a significant percentage came from late-stage repeat business, while this year a significant percentage will come from new business.
• Fermion agreement validates breadth: A three-year material supplies agreement was signed with Fermion for a set of patented commercial-stage molecules. One non-fluorinated molecule has already shipped qualification batches and received a follow-on order. The deal proves Navin's credibility to supply molecules outside its core fluorination chemistry.
• Contract economics: Management indicated the agreement could be worth roughly \$40 million over three years, but stressed it is not a take-or-pay contract and does not require dedicated investment. Navin will be a second supplier alongside an existing European source.
• CEO resignation: The CDMO business head, Ravi, has resigned to start his own venture. Two internal candidates are in the final stages of evaluation, with a decision expected in the coming weeks.
• FY24 outlook: Management expects only a nominal increase in CDMO revenue this year, with a significant uptick in the following year. The growth trajectory is tracking similarly to last year.

Welling: "I think more than the revenue per se, what it really does for us is, a, it proves our credibility now to supply molecules outside of our core fluorination."

Margin Structure and Cost Dynamics

• Similar operating margins, different contribution profiles: Contribution margins vary widely across businesses, but EBITDA margins are very similar because higher contribution-margin businesses also carry higher fixed cost loads. Quarter-to-quarter overall margins shift depending on which business sells more.
• Other expenses normalised: Other expenses dropped sharply QoQ from INR138 crores to INR95 crores. The prior quarter included roughly INR15 crores of one-offs (consultancy charges, high repair costs, provisions), while the balance decline reflected lower CDMO activity and plant shutdowns.
• Working capital target: Management is targeting 90 to 100 days of working capital and has initiated actions, with progress expected to show in the first half of FY24.

Welling: "Our contribution margins in different businesses are very different... EBITDA margins are very, very similar because some of these higher contribution margin businesses also have a higher fixed cost load, but overall, the operating margins are very similar, but then quarter-to-quarter, our overall margins change depending on which business is actually selling more."

Capex Pipeline and New Capabilities

• Surat new capability: The Board approved INR30 crores for a completely new technology platform in Surat. It will take 15 to 18 months to build and is expected to attract new projects in agrochemical and other businesses.
• cGMP4 progressing: Detailed engineering for the cGMP4 facility is advancing and will be presented to the Board for approval in the coming quarters. The \$16 million molecule, which is performing well with another large biopharma company, is expected to see further scale-up in calendar year 2024 and will inform the cGMP4 investment case.
• R32 and agro capex: The R32 plant is stabilizing with sales expected to begin in Q2 FY24. The dedicated agrochemical specialty capex is on track for commissioning by the end of this calendar year.
• AHF project: The AHF project is progressing on schedule, with basic engineering technology and equipment agreements signed with a global leader. The capacity is aimed at rising demand in pharmaceuticals, agrochemicals, and emerging areas like EV battery chemicals and solar.

Demand Environment and Competitive Positioning

• Destocking, not demand destruction: For all four plus one molecule mapped in the new Dahej assets, end-market demand continues to be very strong. The current volatility is driven by destocking, not underlying demand weakness.
• MPP ramp-up delayed but intact: The multipurpose plant is expected to run at lower utilization this year as planned, with optimal levels from calendar year 2024 onward. Two of four molecules are seeing issues, but this is not resulting in a sales downturn this year. Destocking is expected to be resolved by next year, and if it reverses to restocking, a significant demand uptick is possible based on initial customer conversations.
• China strategy: Management has been deliberate in selecting value chains with no direct competition from China. Most new molecules in Dahej and new opportunities are not seeing an immediate threat from Chinese competitors.

Welling: "If you actually read my commentary over the last, let's say, two years, one of the things that I have constantly been saying whenever there was a question related to China plus one, I have always mentioned that China will be back, and China will be back with vengeance, hence it is extremely important to select the value chains that you want to play in very, very carefully."

Guidance & Commitments

Key Metrics